Biotechnology entrepreneur. Founder and CEO of NovaBiotics. Immunologist designing and developing much needed novel antimicrobial strategies for over 20 years.
Aberdeen, UK
Joined July 2014
- Tweets801
- Following211
- Followers515
- Likes1.2K
Not only did the ‘driver’ ensure a 2 min silence either side of 1100, but I’m sure he dipped a wing at 1100 (not checking in case that was just a headwind coincidence…) Well done #Loganair
Deborah O'Neil retweeted
That's one week down of Curious 2023 - but there's still loads to come...
We've had a fantastic first week delving under the surface - from forensic science to primate research and everything in between!
Don't miss out on our exciting programme & visit rse-curious.com
Looking forward very much to this event at the @RoyalSocEd. Please come along & join us! #WomenInSTEM
Leaders, pioneers, icons ✨👑
Join us for this event as we bring four of these world-leading scientists from the exhibition to the stage to share their inspirations and journeys through their STEM careers.
rse-curious.com/women-in-sci…
Deborah O'Neil retweeted
It’s the things we do that mean the most. 🛹
#TheBeginner
Deborah O'Neil retweeted
Community Acquired Pneumonia (CAP) is an unmet global health & socioeconomic issue. Prevalence is increasing and a challenging winter CAP season driven by COVID, influenza & bacterial infections looms. Read more about NM002, our immunomodulator-antimicrobial candidate therapy 👇
Deborah O'Neil retweeted
“I can no longer, in good conscience, live with this Prime Minister. Either he goes, or I do”
Deborah O'Neil retweeted
Are you a singing scientist or healthcare professional?
We need your help!! We’re recruiting our chorus for @edfringe. Auditions 14th & 21st of May in Edinburgh. Apply now at mouldthatchangedtheworld.com
Deborah O'Neil retweeted
The #EU Pharma Legislation revision is on the horizon. What solutions do #SMEs need from our policymakers to unlock the innovation potential to tackle #AMR? Check out this video and don’t hesitate to spread the voice of SMEs too: like, share, and comment! bit.ly/3K057dv
Deborah O'Neil retweeted
Showcase session at #LifeSciencesSummit explores work of innovative #biotech and #healthtech businesses at different stages of growth @dyneval @EnteroBiotix @NovaBiotics @debsoneil Dr Rabinder Buttar @thetimesscot @SundayTimesScot #ONELifeSciences #BioHub @aberdeenuni
Deborah O'Neil retweeted
Today is the 5th #WorldAspergillosisDay, raising awareness of the diseases & complications of existing conditions #Aspergillus causes. Our novel antifungal peptide NP339 is being developed for invasive & respiratory Aspergillus infections.
#thinkfungus #drugdiscovery #immunology
A great opportunity 👇👇
📣 Apply now for the #ONELifeSciences Boot Camp & Accelerator 👇
🌟 Test & develop your #lifesciences business concept
🌟 Create a compelling commercial proposition
🌟 Access up to £10k grant funding for your next steps
opportunitynortheast.com/lif…
#startup #Aberdeen #NEERSF
NovaBiotics Ltd #NACFC2021 poster presentation with @dougfp78 'on' very soon...👇👇
Don't miss @dougfp78 presenting new data in Poster #431 on 'Anti-virulence activities of cysteamine and protection from Pseudomonas toxicity in a Galleria mellonella model'
NACFC today at 1.10pm EST or 5.10pm GMT
#NACFC21 #CysticFibrosis #Antimicrobials #drugdiscovery2021
Deborah O'Neil retweeted
Aberdeen biotech pioneer @NovaBiotics @debsoneil to share drug development progress at @eurconfmedmycol #TIMM2021 conference at @PandJLive in #Aberdeen, reports @pressjournal #lifesciences #biotech @aberdeenuni @SBF_ABDN @AFGTweets @Invest_Aberdeen @LifeSciScot
Deborah O'Neil retweeted
We urge #HERA to effectively support R&D in antimicrobial resistance. Read our full statement on the recent proposal here: beam-alliance.eu/beam-allian…
Our latest publication, drilling further down into the mechanism of NM001 against Pseudomonas aeruginosa, still a major, poorly served driver of pathology in #cysticfibrosis. NM001 has potential in #CF, but also in other respiratory disease & against other bacterial pathogens👇👇
Very pleased to share further mechanistic insights highlighting the potential of our NM001 therapy candidate for #cysticfibrosis. Our latest publication is now out in a special Pseudomonas aeruginosa focused edition of @FrontiersIn frontiersin.org/article/10.3…
Congratulations to all of this years' unstoppable #EOYUK finalists 👏✨
This Post is from an account that no longer exists. Learn more
Looking forward to tomorrow’s @RoyalSocEd Tea & Talk session…
An open discussion reflecting on the the discovery and development of new or re-purposed treatments to tackle the Covid-19 with @debsoneil FRSE, Chief Executive & Scientific Officer @NovaBiotics 💊
📆 19 August
🕢 11:00 BST
🎫 rse-curious.com/developing-t…
👇👇 Great news for the @NovaBiotics team this week & we very much hope NM002's potential is realised & benefits patients hospitalised in ICU with CAP.
Delighted to announce inclusion of our NM002 candidate in the Phase 3 REMAP-CAP global clinical trial for Community Acquired Pneumonias (CAP), including COVID19 CAP, in hospitalized patients in ICU. novabiotics.co.uk/novabiotic…
#REMAPCAP #CommunityAcquiredPneumonia #COVID19 #NIHR
Rounding out CF Week in the UK, 2 abstracts accepted for presentation @ the North American Cystic Fibrosis Conference: new data further elucidating mechanisms of cysteamine (NM001) against 2 key CF bacterial pathogens, Pseudomonas & Burkholderia.
#CFWeek #NACFC #cfawareness
